Assistant Professor, Biochemistry and Molecular Biology

Maneesh Jain, PhD

Phone: 402-559-7667
Fax: 402-559-6650
Email: mjain@unmc.edu

Education/Training:
Ph.D., IMTECH, Chandigarh (JNU), INDIA, 2002

Research: 

Research Interest: Development of diagnostics and therapeutics against cancer and allied diseases

My interest has been to develop antibody-based strategies for targeted therapy and diagnosis of diseases, particularly cancer. Our research involves development of genetically engineered antibody fragments for improved radioimmunotherapy of solid tumors. We are trying to optimize radioimmunotherapy of solid tumors by modifying the molecular design of antibody fragments and introducing sequences that will enhance the uptake and/or retention of radiolabeled antibodies in the tumor tissues without altering their distribution in non-target tissues. Recently, we demonstrated the utility of cell penetrating peptides in improving the tumor retention antibody fragments. 

The other area of our research involves development of serum assays for the early diagnosis of lethal pancreatic cancer. We are trying several approaches to develop sensitive mucin-based serum assays utilizing the antibodies that we have generated. In collaboration with several groups we are trying to develop a multimarker nanoparticle-based assay for early diagnosis of pancreatic cancer. We are also trying to use the antibodies for disrupting the signaling pathways mediated by their targets for therapeutic intervention and engineering the antibodies for human use. Additionally, we are trying to use the antibodies and antibody fragments for the delivery nanoparticle-encapsulated drugs to various cancers. The following projects are currently in progress:

  1. Early diagnosis of pancreatic cancer. The project involves development of a mucin-based serum assays(s) for the early detection of pancreatic cancer using various approaches.
  2. Therapy against prostate and other cancer using radiolabeled antibody constructs. We are interested in developing a multi-antigen (EGFRvIII, MUC4 and TAG72) targeted radioimmunotherapy using a cocktail of antibody fragments.
  3. Studying the involvement of altered signaling pathways in cancer and exploiting the information cancer therapy. We are trying to understand the role(s) of RUNX family transcription factors in the pathogenesis of pancreatic cancer. Specific focus is on the identification of target gene(s) regulated by RUNX3 and their involvement in the development and progression of pancreatic cancer.
  4. Studying the involvement of altered EGFR signaling in the development of pancreatic cancer. We are studying the role of mutant EGFR receptors, particularly EGFRvIII, in the pancreatic cancer pathogenesis. These studies will form the basis of developing new therapeutic strategies using anti-EGFRvIII-specific antibodies for targeting pancreatic cancer.

Publications:

Seshacharyulu, P, Ponnusamy, MP, Haridas, D, Jain, M, Ganti A.K and Batra S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opinions on Therapeutic Targets, 16, 15-31, 2012.

Kaur S, Venktaraman G, Jain M, Senapati S, Garg P.K and Batra, S.K. Recent advances in antibody-based imaging for solid tumor. Cancer Letters, 315, 97-111, 2012.

Mukhopadhyay, P; Chakraborty, S, Ponnusamy, M.P., Lakshmanan, I., Jain, M and Batra, S.K.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. BBA Reviews on Cancer, 1815(2):224-240, 2011.

Jain M, Kaur S, and Batra SK. Modulation of Biological Impediments for Radioimmunotherapy of Solid Tumors. Targeted Radionuclide Therapy (Publisher: Lippincott; Ed- Tod W Speer), 182-190, 2010.

Ponnusamy, M.P., Lakshmanan, I., Jain, M, Das, S., Chakraborty, S., Dey, P., and Batra S.K. MUC4 mucin induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene, 29(42):5741-54, 2010.

Munro EG, Jain M, Oliva E, Kamal N, Lele SM,  Lynch MP, Guo L, Fu K, Sharma P, Remmenga S, Growdon WB, Davis JS, Rueda BR and Batra SK. Upregulation of MUC4 in cervical squamous cell carcinoma: Pathological significance. Int J Gynecol Pathol 28(2):127-33, 2009.

Singh, A.P., Shantibusan S., Ponnusamy. M.P., Jain, M, Lele, S.M., Davis J.S., Remmenga.S and Batra S.K. Clinical potential of mucins in diagnosis, prognosis and therapy of ovarian cancer. Lancet Oncology 9, 1076-1085, 2008.

Chakraborty S., Jain M, Sasson A., and Batra SK. MUC4 as a Diagnostic Marker in Cancer. Expert Opinion in Medical Diagnostics, 2 (8): 891-910, 2008.

Ponnusamy, M.P, Singh, A.P., Jain M, and Batra, S.K. MUC4 mucin activates HER2 signaling and enhances the motility of human ovarian cancer cells. British Journal of Cancer, 99(3):520-6, 2008.

Davda J.P., Jain M, Batra S.K., Gwilt P.R., and Robinson, D.H. A Physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. International Immunopharmacology, 8(3), 401-413, 2008.

Jain, M, Venkatraman,G. and Batra,S.K. Cell-penetrating peptides and antibodies: a new direction for optimizing radioimmunotherapy.  Eur J Nucl.Med.Mol.Imaging., 34(7):973-7, 2007.

Jain, M, Kamal N., and Batra,S.K. Engineering of antibodies for clinical application. Trends in Biotechnology, 25(7):307-16, 2007.

Ponnusamy,M.P., Venkatraman,G., Singh,A.P., Chauhan,S.C., Johansson,S.L., Jain, M, Smith,L., Davis,J.S., Remmenga,S.W. and Batra,S.K. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Letters 251, 247-257, 2007.

Jain, M, Venkatraman,G. and Batra,S.K. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation.  Clinical Cancer Research, 13: 1374-1382, 2007.

Senapati S, Ponnusamy MP, Singh AP, Jain, M, and Batra SK . MUC16 (mucin 16, cell surface associated). Atlas Genet Cytogenet Oncol Haematol. October 2007.  URL : http://AtlasGeneticsOncology.org/Genes/MUC16ID41455ch19q13.html

Current Funding:

DHHS/NIH/NCI
Early diagnosis of pancreatic cancer
9/1/2010 - 6/30/2015

DHHS/NIH/NCI
Novel combination therapy against pancreatic cancer
4/1/2011 - 3/31/2013

DHHS/NIH/NCI
EGFRvIII in pancreatic cancer
6/1/2009 - 6/30/2012

DHHS/NIH/NCI
Nebraska Center for Nanomedicine
6/15/2012 - 6/30/2013

DHHS/NIH/NCI
Pancreatic tumor microenvironment network (TMEN)
9/26/2011 - 7/31/2016

 

;